Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival.

[1]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[2]  Soo-Nyung Kim,et al.  Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma. , 2015, Journal of the American Academy of Dermatology.

[3]  M. Samur.  RTCGAToolbox: A New Tool for Exporting TCGA Firehose Data , 2014, PloS one.

[4]  P. Fox,et al.  Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations , 2014, Clinical Cancer Research.

[5]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[6]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[7]  Charis Eng,et al.  Germline and somatic KLLN alterations in breast cancer dysregulate G2 arrest. , 2013, Human molecular genetics.

[8]  Charis Eng,et al.  Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation. , 2013, The Journal of clinical endocrinology and metabolism.

[9]  S. Kweon,et al.  BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas. , 2013, The Journal of investigative dermatology.

[10]  L. Chin,et al.  Melanoma: from mutations to medicine. , 2012, Genes & development.

[11]  A. Riggs,et al.  Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation , 2012, Proceedings of the National Academy of Sciences.

[12]  C. Sotiriou,et al.  Evaluation of the Infinium Methylation 450K technology. , 2011, Epigenomics.

[13]  K. Gunderson,et al.  High density DNA methylation array with single CpG site resolution. , 2011, Genomics.

[14]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[15]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[16]  J. Choi,et al.  Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis , 2011, The British journal of dermatology.

[17]  Derek Y. Chiang,et al.  MapSplice: Accurate mapping of RNA-seq reads for splice junction discovery , 2010, Nucleic acids research.

[18]  P. Helmbold,et al.  Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. , 2010, The Journal of investigative dermatology.

[19]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Victor G Prieto,et al.  Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma , 2009, Clinical Cancer Research.

[21]  Yiling Lu,et al.  AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.

[22]  O. Fodstad,et al.  Epigenetics in human melanoma. , 2009, Cancer control : journal of the Moffitt Cancer Center.

[23]  R. Parsons,et al.  The role of PTEN signaling perturbations in cancer and in targeted therapy , 2008, Oncogene.

[24]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[25]  Alessandra Marini,et al.  Epigenetic silencing of the PTEN gene in melanoma. , 2006, Cancer research.

[26]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[27]  D. Polsky,et al.  PTEN Expression in Melanoma: Relationship with Patient Survival, Bcl-2 Expression, and Proliferation , 2005, Clinical Cancer Research.

[28]  K. Aldape,et al.  PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. , 2005, Human pathology.

[29]  R. Parsons,et al.  PTEN: life as a tumor suppressor. , 2001, Experimental cell research.

[30]  C. Eng,et al.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. , 2000, The American journal of pathology.

[31]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[32]  F. Haluska,et al.  Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines , 1998, Oncogene.

[33]  R. Vessella,et al.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P. Guldberg,et al.  Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. , 1997, Cancer research.

[35]  David R. Kaplan,et al.  Regulation of Neuronal Survival by the Serine-Threonine Protein Kinase Akt , 1997, Science.

[36]  A. Feinberg,et al.  Hypomethylation of DNA from benign and malignant human colon neoplasms. , 1985, Science.

[37]  K. Flaherty,et al.  Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. , 2012, European journal of cancer.

[38]  Soma Das,et al.  PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma , 2001, International journal of cancer.